TLDR VanEck files first JitoSOL ETF, bridging Solana staking with Wall Street. JitoSOL ETF brings liquid Solana staking yields to traditional investors. VanEck pushes Solana mainstream with first-ever regulated JitoSOL ETF. SEC clarity fuels VanEck’s JitoSOL ETF, linking staking rewards to ETFs. JitoSOL ETF opens new gateway for Solana staking via traditional finance. VanEck has [...] The post VanEck Files for First-Ever JitoSOL ETF: Liquid Staking Goes Mainstream appeared first on CoinCentral.TLDR VanEck files first JitoSOL ETF, bridging Solana staking with Wall Street. JitoSOL ETF brings liquid Solana staking yields to traditional investors. VanEck pushes Solana mainstream with first-ever regulated JitoSOL ETF. SEC clarity fuels VanEck’s JitoSOL ETF, linking staking rewards to ETFs. JitoSOL ETF opens new gateway for Solana staking via traditional finance. VanEck has [...] The post VanEck Files for First-Ever JitoSOL ETF: Liquid Staking Goes Mainstream appeared first on CoinCentral.

VanEck Files for First-Ever JitoSOL ETF: Liquid Staking Goes Mainstream

2025/08/23 01:30
3 min read

TLDR

  • VanEck files first JitoSOL ETF, bridging Solana staking with Wall Street.
  • JitoSOL ETF brings liquid Solana staking yields to traditional investors.
  • VanEck pushes Solana mainstream with first-ever regulated JitoSOL ETF.
  • SEC clarity fuels VanEck’s JitoSOL ETF, linking staking rewards to ETFs.
  • JitoSOL ETF opens new gateway for Solana staking via traditional finance.

VanEck has officially filed a registration with the SEC for the first JitoSOL ETF, targeting Solana’s liquid staking market. The new ETF aims to give exposure to JitoSOL, a liquid staking token that represents staked SOL and its yield. This move brings tokenized Solana staking directly into traditional finance infrastructure.

The JitoSOL ETF seeks to track the price of JitoSOL and provide holders with access to staking rewards through a familiar ETF structure. The fund will allow shares to be bought and sold through brokers, offering an accessible route to blockchain-based returns. VanEck’s submission arrives as regulators clarify the legal standing of liquid staking in ETF models.

VanEck Proposes Regulated Exposure to JitoSOL Staking

The VanEck JitoSOL ETF intends to operate under a structure designed for secure and regulated trading of a crypto-linked product. It will use the MarketVector JitoSOL Benchmark Rate to determine pricing, selecting data from top exchanges reviewed by industry analytics. The ETF will issue and redeem shares in blocks of 25,000, either in cash or in-kind, through authorized participants.

JitoSOL, the core asset of the ETF, enables users to trade staked SOL value while continuing to earn staking rewards on-chain. The fund bridges on-chain yield mechanics with traditional investment channels, expanding staking access through regulated products. All JitoSOL tokens will be held by a qualified custodian on behalf of the ETF.

The registration notes that the ETF will continuously offer shares and price them daily, reflecting the underlying value of JitoSOL less operational expenses. With this format, retail and institutional accounts can engage with Solana’s staking yield without managing crypto wallets or blockchain interactions. VanEck has positioned the JitoSOL ETF as a first-of-its-kind offering built around liquid staking.

Regulatory Green Light Opens the Door for JitoSOL-Based ETFs

The SEC’s recent guidance confirmed that specific liquid staking activities, including those involving JitoSOL, do not meet securities criteria. This ruling clears the path for products like the JitoSOL ETF, which aims to comply fully with evolving federal standards. VanEck’s proposal leverages this clarity to advance a compliant product framework for token-based staking.

The Jito Foundation revealed that the fund is the result of sustained engagement with the SEC and crypto task force members. This collaboration helped define how JitoSOL fits within ETF structures, establishing it as a valid instrument for wrapped investment exposure. The foundation supports the use of regulated wrappers to bring staking to a broader base of capital allocators.

The ETF proposal coincides with a broader shift toward crypto-favorable regulation. The SEC recently approved changes that allow in-kind creation for crypto ETFs and opened the door to spot Ethereum and Bitcoin ETFs. These developments suggest that JitoSOL ETF approval may follow the same regulatory path.

 

The post VanEck Files for First-Ever JitoSOL ETF: Liquid Staking Goes Mainstream appeared first on CoinCentral.

Market Opportunity
Everscale Logo
Everscale Price(EVER)
$0.00308
$0.00308$0.00308
-0.64%
USD
Everscale (EVER) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

And the Big Day Has Arrived: The Anticipated News for XRP and Dogecoin Tomorrow

And the Big Day Has Arrived: The Anticipated News for XRP and Dogecoin Tomorrow

The first-ever ETFs for XRP and Dogecoin are expected to launch in the US tomorrow. Here's what you need to know. Continue Reading: And the Big Day Has Arrived: The Anticipated News for XRP and Dogecoin Tomorrow
Share
Coinstats2025/09/18 04:33
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Rising Altcoin Inflows Signal Potential Market Sell-Off: CryptoQuant

Rising Altcoin Inflows Signal Potential Market Sell-Off: CryptoQuant

        Highlights:  Inflows of altcoins in exchanges have surged by 22% in early 2026. An increase in deposits indicates a growing sell-side pressure. The 
Share
Coinstats2026/02/22 02:03